x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Psychopharmacology and Psychiatry Updates

Psychopharmacology Institute

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

health & fitness medicine

All Episodes

11:40

Beyond Monotherapy: Mixed Episode Management

Psychopharmacology and Psychiatry Updates ·

2025/11/02

In this episode, we explore the critical decision of when to add lithium or valproate to second-generation antipsychotics in mixed manic episodes. Should you rush to combination therapy under managed care pressure, or does patience with strategic benzodiazepine bridging lead to better outcomes? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: An Update on Bipolar Mania Algorithm Choosing Between Valproate or Lithium Augmentation for Bipolar

en

08:58

Old Drug, New Perspectives: Disulfiram's and...

Psychopharmacology and Psychiatry Updates ·

2025/10/28

In this episode, we explore a provocative argument for reconsidering disulfiram as a first-line treatment for alcohol use disorder. Could this decades-old medication, often dismissed as outdated and dangerous, actually be more effective than newer alternatives when used in appropriately selected patients? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Alcohol Use Disorder: Should Disulfiram Be First-Line?

en

13:52

Quetiapine vs. Lithium in Mixed Bipolar States

Psychopharmacology and Psychiatry Updates ·

2025/10/23

In this episode, we explore the complex pharmacological management of mixed mania, a challenging bipolar presentation affecting up to 40% of manic episodes. Why do traditional mood stabilizers like lithium fall short, and which second-generation antipsychotics emerge as first-line treatments for this dual-symptom condition? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Lithium: How to Manage Dosage and Side Effects Managing Renal Side

en

17:19

Psychedelic-Assisted Therapy: Redefining Treatment

Psychopharmacology and Psychiatry Updates ·

2025/10/18

In this episode, we explore psychedelic-assisted therapy in clinical practice, examining how these treatments differ fundamentally from traditional pharmacotherapy. Can psychiatrists reconcile mystical experiences with evidence-based medicine while navigating the complex therapeutic paradigm of preparation, 8-hour sessions, and integration work? Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry

en

13:50

Lurasidone's Therapeutic Window: Is Less More?

Psychopharmacology and Psychiatry Updates ·

2025/10/13

In this episode, we explore groundbreaking research revealing that lower doses of lurasidone (40-60mg) may be more effective for bipolar depression than higher doses. Could we be over-medicating our patients when the sweet spot for both efficacy and tolerability lies in this unexpected lower range? Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Lurasidone for Bipolar Depression: What Is the Optimal Dose?

en

11:30

Beyond Black Box Warnings: Choosing Antipsychotics in...

Psychopharmacology and Psychiatry Updates ·

2025/10/08

In this episode, we explore a compelling comparison between olanzapine and risperidone for managing behavioral symptoms in dementia patients. Are the delusions we see in Alzheimer's disease actually true delusions, or something entirely different that requires a new treatment approach? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 73 Alzheimer’s Disease: Olanzapine vs. Risperidone for BPSD

en

11:14

SSRIs and Psychedelics: Drug Interactions

Psychopharmacology and Psychiatry Updates ·

2025/10/03

In this episode, we explore the complex drug-drug interactions between psychedelics and psychiatric medications. Do SSRIs really blunt psychedelic effects, or is this just clinical folklore? We'll examine surprising new research and discuss potentially dangerous combinations every psychiatrist should know. Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry Examining the Combined Use of Psychedelics and

en

14:06

Standard vs. High Doses: Rethinking Bipolar...

Psychopharmacology and Psychiatry Updates ·

2025/09/28

In this episode, we challenge the conventional wisdom of “what gets them well keeps them well” by exploring groundbreaking Finnish research on bipolar disorder medication dosing. Does maintaining patients on high doses actually improve long-term outcomes, or could standard doses be the optimal strategy for relapse prevention? Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Bipolar Disorder Maintenance: What’s the Optimal

en

14:11

Psychedelics and Brain Networks

Psychopharmacology and Psychiatry Updates ·

2025/09/23

In this episode, we explore how psychedelics like psilocybin disrupt the brain's default mode network, creating windows of neuroplasticity that correlate with mystical experiences and therapeutic breakthroughs in treatment-resistant depression, anxiety, and addiction. Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry How Psychedelics Influence Brain Networks

en

16:33

LAIs vs Oral Antipsychotics: Mortality Data and...

Psychopharmacology and Psychiatry Updates ·

2025/09/18

In this episode, we explore groundbreaking research showing how long-acting injectable antipsychotics can literally save lives in schizophrenia treatment. Could choosing the right medication delivery method be the difference between a patient thriving or facing premature death by 15-20 years? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Long-Acting Injectables: Superior for Reducing Mortality in

en

15:55

The Science Behind Psychedelic Therapy

Psychopharmacology and Psychiatry Updates ·

2025/09/13

In this episode, we explore the fascinating mechanisms behind psychedelic drugs in psychiatry, examining how substances like psilocybin and LSD work through 5-HT2A receptors to promote neuroplasticity. What if these compounds are hijacking an ancient stress response system designed to help us rapidly adapt to survive? Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry The Mechanisms and Effects of

en

12:11

Which Antidepressant Causes the Most Weight Gain?

Psychopharmacology and Psychiatry Updates ·

2025/09/08

In this episode, we explore groundbreaking research comparing weight gain across eight common antidepressants. Using data from 183,000 patients, this study finally provides concrete numbers to answer the question patients ask most: How much weight will I gain on this medication? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 72 Which Antidepressants Cause the Most Weight Gain?

en

12:14

Lisdexamfetamine for Binge Eating Disorder

Psychopharmacology and Psychiatry Updates ·

2025/09/03

In this episode, we explore lisdexamfetamine as the first FDA-approved medication for binge eating disorder. Can one medication effectively treat both ADHD and binge eating simultaneously? We examine the evidence, duration of treatment, and strategies for addressing patient ambivalence in eating disorder pharmacotherapy. Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Binge Eating Disorder

en

11:27

Beyond Weight Loss: GLP-1 Agonists and Alcohol Use...

Psychopharmacology and Psychiatry Updates ·

2025/08/29

In this episode, we explore groundbreaking Swedish research on GLP-1 receptor agonists as a potential new treatment for alcohol use disorder. Could diabetes medications like semaglutide revolutionize addiction treatment where traditional therapies have fallen short? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 72 Which Antidepressants Cause the Most Weight Gain?

en

11:26

Antidepressants vs. Anticonvulsants for Binge Eating

Psychopharmacology and Psychiatry Updates ·

2025/08/24

In this episode, we explore pharmacotherapy for binge eating disorder, examining how antidepressants, anticonvulsants, and emerging treatments target different patient goals. Should your treatment focus on stopping binge episodes or achieving weight loss? We discuss evidence-based approaches to align medication choices with patient priorities for optimal outcomes. Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating

en

11:19

Lithium Levels: Finding the Right Therapeutic Target

Psychopharmacology and Psychiatry Updates ·

2025/08/19

In this episode, we explore the confusing world of lithium therapeutic levels with Dr. Paul Zarkowski. Why do different labs recommend different ranges for the same medication? We examine expert consensus on optimal dosing strategies for both acute treatment and maintenance therapy in bipolar disorder. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 What is the Optimal Therapeutic Range for Lithium in Bipolar

en

09:28

Antidepressants Beyond Depression: Applications in...

Psychopharmacology and Psychiatry Updates ·

2025/08/14

In this episode, we explore evidence-based pharmacotherapy for bulimia nervosa, including why higher doses of SSRIs work better than standard dosing, which medications to avoid completely, and how antidepressants can be effective even without depression being present. Why does fluoxetine require 60 mg daily for optimal results? Faculty: Scott Crow M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Bulimia Nervosa:

en

12:10

Metformin and Antipsychotic-Induced Weight Gain: An...

Psychopharmacology and Psychiatry Updates ·

2025/08/09

In this episode, we explore groundbreaking research on managing antipsychotic-induced weight gain through a comprehensive network meta-analysis. Could the combination of low-dose metformin and lifestyle modifications be the game-changer that helps patients maintain both mental stability and physical health? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Antipsychotic-Induced Weight Gain: Best Management Strategies

en

08:17

Monthly Injections, Long-Term Recovery: Naltrexone...

Psychopharmacology and Psychiatry Updates ·

2025/08/04

In this episode, we explore extended-release naltrexone for opioid use disorder, examining its unique role as a pure antagonist in patients who require safety-sensitive careers. How do we successfully navigate the challenging initiation period when patients must be opioid-free for a week? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Examining the Efficacy of Extended-Release Naltrexone OUD

en

12:03

Antipsychotics and Aspiration Risk

Psychopharmacology and Psychiatry Updates ·

2025/07/30

In this episode, we explore the surprising link between antipsychotic medications and pneumonia risk. Did you know that pneumonia is the fourth leading cause of death in schizophrenia patients, and certain medications increase this risk in unexpected ways? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Pneumonia in Schizophrenia: Which Antipsychotics Pose the Highest Risk for?

en

411 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown